SMITHS-DETECTION
10.10.2019 08:02:08 CEST | Business Wire | Press release
Global threat detection and security technologies company, Smiths Detection is showcasing for the first time an integrated checkpoint solution at inter airport Europe 2019, which harnesses biometric technology to enable risk-based screening practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005541/en/
With air passenger growth predicted to double by 2037, the aviation industry will be challenged to support this capacity growth whilst providing operational efficiencies and meeting shifting passenger expectations of the airport experience.1 To cope with this growth, biometric technology is being increasingly adopted at airport Border Control gates, bag drop and boarding gates.
As leaders in providing checkpoint solutions to airports across the world, Smiths Detection has partnered with experts in the field of biometry to, for the first time, create a proof of concept which integrates biometric identity management solutions with class-leading screening solutions. Inter airport delegates are invited to experience the biometric capable checkpoint in action – which also employs Smiths Detection’s advanced CT scanner, HI-SCAN 6040 CTiX , the iCMORE Weapons automatic object recognition capability and the advanced tray return system, iLane.evo .
Biometrics is the ‘unique identifier’ for passengers, and through integration of biometrics directly into the checkpoint, passengers can be matched with their trays to enable real-time risk-based screening. Risk-based screening is designed to increase operational efficiency and effectiveness through continual risk assessments relevant to the individual passenger journey, resulting in shorter and easier journeys for passengers.
Through passenger and tray identification, new data insights can be gathered to inform decision making at airports - based on flights, airlines or destinations. Matching passengers with trays also enables the sharing of screening results with transit or arrival airports, and the combination of hold baggage and checkpoint screening results.
“At Smiths Detection, we’re dedicated to delivering a seamless passenger journey and we are very excited to be driving biometric checkpoint technology forward in a rapidly developing marketplace,” said Smiths Detection Vice President Europe, Africa and Marketing Tony Tielen . “As a trusted partner to airports across the world, we are working with the aviation industry to deliver risk-based screening at departure, transit and arrival airports to streamline the checkpoint journey to make it even safer and more efficient.”
“Biometrics is an urgently needed solution to provide seamless checkpoint security,” said Global Market Director Aviation, Richard Thompson . “Ever increasing air passenger traffic plus advances in biometrics, artificial intelligence and integrated screening technology mean that risk-based screening is now firmly on the fast track. We look forward to offering a preview of the checkpoint solution of the future to delegates at inter airport Europe 2019.”
Enquiries:
If you would like to speak with someone regarding this press release and/or preview this checkpoint solution, Smiths Detection will be presenting at Stand 410, Hall B6 at inter airport Europe.
References and data points:
- At the beginning of 2018, SITA, the airlines technology supplier, reported that 77% of airports and 71% of airlines were planning major programs or R&D in biometric ID management over the next five years.
- Airlines are responding to demands from passengers as 57% of passengers would "definitely use biometrics" if it helps them get quicker through the boarding process, according to SITA.
- According to the IATA 2018 Passenger Survey , 45% of air travellers choose biometric identification as a replacement of their passport.
- Over 65 percent of passenger’s were inclined towards sharing additional personal information to speed up their processing at the airport. Speed and convenience are paramount, according to IATA .
Recent press releases:
- Smiths Detection launches new security scanner specifically developed for air cargo screening
- Smiths Detection secures $96.8m contract to provide checkpoint CT systems to Transportation Security Administration (TSA)
- Smiths Detection’s Largest Ever Order for HBS Systems Confirmed by Spanish Airport Operator, Aena
###
About Smiths Detection
Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
Our mission is to help make the world a safer place – and do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.
For more information visit http://www.smithsdetection.com .
About inter airport Europe
From 8 – 11 October 2019, inter airport Europe 2019, the 22nd International Exhibition for Airport Equipment, Technology, Design and Services will take place at the Munich Trade Fair Centre in Germany.
For manufacturers and suppliers of airport equipment, technology, design and services, inter airport Europe provides the opportunity to meet specialists from airports, airlines, air cargo carriers as well as aviation support from all over the world looking to invest in future-oriented, modern solutions for the interconnected airport. The world’s leading airport exhibition is renowned for covering the most comprehensive range of products and services for the entire airport: technology and services for ground handling, airport equipment, terminal operations, airport IT solutions and airport design.
For more information visit https://www.interairporteurope.com/welcome#/
1 https://www.iata.org/pressroom/pr/Pages/2018-10-24-02.aspx
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005541/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
